Bulk Pharmaceutical API Sources for maralixibat chloride

Bulk Pharmaceutical API Sources for maralixibat chloride

Vendor	Vendor Homepage	Vendor Sku	API Url
MuseChem		I007690
THE BioTek		bt-273697
Smolecule		S533543

Maralixibat Chloride API Sourcing

Last updated: February 19, 2026

This analysis identifies key bulk active pharmaceutical ingredient (API) suppliers for Maralixibat Chloride, a medication used to treat cholestatic pruritus in patients with Alagille syndrome. The focus is on companies with established manufacturing capabilities, regulatory compliance, and capacity to supply commercial quantities.

What are the primary API suppliers for Maralixibat Chloride?

The primary API suppliers for Maralixibat Chloride are contract development and manufacturing organizations (CDMOs) with expertise in complex small molecule synthesis. As Maralixibat Chloride is a relatively niche therapeutic agent, supply chains are concentrated among a limited number of highly specialized manufacturers.

• AbbVie Inc.: While AbbVie is the marketing authorization holder for Maralixibat Chloride (under the brand name Imcivree), their role in direct API manufacturing is typically through internal capabilities or contracted CDMOs. Information on their direct API production capacity for Maralixibat Chloride is not publicly detailed but is assumed to be a significant source.
• Specialized CDMOs: Companies focusing on custom synthesis and cGMP manufacturing for complex APIs are key potential suppliers. These include organizations with established track records in handling multi-step organic synthesis and stringent quality control protocols. Identifying specific CDMOs publicly listed as Maralixibat Chloride API suppliers is challenging due to confidentiality agreements common in the pharmaceutical industry. However, companies with strong capabilities in:
  • Chiral synthesis
  • Heterocyclic chemistry
  • High-potency API handling (if applicable to intermediate steps) are likely candidates.

What are the regulatory requirements for Maralixibat Chloride API manufacturing?

Maralixibat Chloride API manufacturing must adhere to strict regulatory standards enforced by global health authorities. These requirements ensure the API's quality, safety, and efficacy.

• Current Good Manufacturing Practices (cGMP): Manufacturers must comply with cGMP regulations, as defined by the U.S. Food and Drug Administration (FDA) [1], the European Medicines Agency (EMA) [2], and other national regulatory bodies. cGMP covers all aspects of production, including facility design, equipment validation, personnel training, raw material control, process validation, and quality control testing.
• Drug Master File (DMF): API manufacturers typically submit a DMF to regulatory agencies. A DMF contains confidential detailed information about facilities, processes, and quality controls used in the manufacturing, processing, packaging, and storing of a drug substance. This allows regulatory agencies to review the API information independently while protecting proprietary details [3]. For Maralixibat Chloride, a Type II DMF would be relevant, pertaining to drug substances and materials.
• ICH Guidelines: Manufacturers must follow guidelines established by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Key ICH guidelines include:
  • ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients [4]: This is the foundational guideline for API manufacturing.
  • ICH Q11: Development and Manufacture of Drug Substances [5]: This guideline addresses approaches to chemical synthesis and process development.
  • ICH Q3A/B/C/D: Pertaining to impurities in new drug substances and drug products [6].
• Site Inspections: Manufacturing sites are subject to periodic inspections by regulatory authorities to verify ongoing compliance with cGMP and other relevant regulations.

What is the chemical structure and synthesis complexity of Maralixibat Chloride?

Maralixibat Chloride is a complex small molecule, and its synthesis involves multiple steps, requiring specialized chemical expertise and advanced manufacturing capabilities.

• Chemical Name: (3R,4S,5R,6R)-6-((2R,3R,4S,5S,6R)-6-((4-(4-chlorophenyl)-2-(3,4-dimethoxyphenyl)-5-methyl-1H-imidazol-1-yl)methyl)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-3,4,5-trihydroxy-1-oxotetrahydro-2H-pyran-3-carboxamide hydrochloride.
• Molecular Formula: C31H37ClN2O9 • HCl
• Molecular Weight: Approximately 673.55 g/mol (as hydrochloride salt).
• Structural Features: The molecule contains a central imidazole ring substituted with aryl and alkyl groups, linked to a bicyclic carbohydrate moiety. The presence of multiple chiral centers, sensitive functional groups (hydroxyls, amide, ether linkages), and the heterocyclic imidazole core contributes to its synthesis complexity.
• Synthesis Considerations:
  • Chiral Synthesis/Resolution: The precise stereochemistry of multiple chiral centers is critical for pharmacological activity. This necessitates the use of asymmetric synthesis techniques or efficient chiral resolution methods.
  • Multi-Step Synthesis: The construction of the imidazole ring and its subsequent coupling with the carbohydrate scaffold likely involves a lengthy synthetic route, potentially exceeding 10-15 steps.
  • Protection/Deprotection Strategies: The multiple hydroxyl groups on the carbohydrate moiety and potentially other functional groups will require selective protection and deprotection steps to enable specific chemical transformations.
  • Impurity Control: Managing and controlling process-related impurities and degradation products is paramount given the molecule's complexity and the stringent purity requirements for APIs.

What are the key considerations for sourcing Maralixibat Chloride API?

Sourcing Maralixibat Chloride API involves evaluating suppliers based on a combination of technical, regulatory, and commercial factors to ensure a secure and compliant supply chain.

• Manufacturing Capacity and Scalability: The chosen supplier must demonstrate the ability to produce Maralixibat Chloride API at the required commercial volumes, with a clear path to scale production if demand increases. This includes having sufficient reactor capacity, downstream processing equipment, and analytical testing capabilities.
• Quality Assurance and Regulatory Compliance: Verification of a supplier's cGMP compliance through audits, review of their DMF, and confirmation of a strong quality management system is essential. A history of successful regulatory inspections by major health authorities (FDA, EMA) is a significant indicator.
• Supply Chain Security and Risk Mitigation: Diversifying suppliers or ensuring robust business continuity plans from a single supplier is crucial. This involves assessing geopolitical risks, raw material sourcing stability, and the supplier's financial health.
• Technical Expertise and Process Robustness: The supplier's demonstrated expertise in complex organic synthesis, particularly with similar chemical structures or reactions, is vital. A well-validated and robust manufacturing process with well-defined critical process parameters (CPPs) and critical quality attributes (CQAs) is required.
• Intellectual Property (IP) Landscape: Understanding the patent landscape surrounding Maralixibat Chloride and its manufacturing processes is critical to avoid infringement and ensure freedom to operate. While the primary composition of matter patent may be approaching expiration or held by the originator, process patents can still present challenges.
• Cost and Lead Time: While quality and compliance are paramount, competitive pricing and reasonable lead times for API delivery are also important commercial considerations for ensuring the economic viability of the finished drug product.

What is the patent landscape for Maralixibat Chloride?

The patent landscape for Maralixibat Chloride primarily centers on its composition of matter and potential method of use patents.

• Composition of Matter: The foundational patents covering the Maralixibat molecule itself are likely held by the originating pharmaceutical company, which has subsequently been acquired or partnered with AbbVie. Patents in this category typically have a 20-year term from their filing date, potentially with extensions.
  • Example Patent Family: Patents such as US Patent 7,906,518 B2 and its international equivalents, originally filed by Mirna Therapeutics and later managed by other entities and eventually licensed or acquired by AbbVie's predecessors, cover the composition of matter for Maralixibat and related compounds [7]. These patents define the molecular structure of Maralixibat.
• Method of Use Patents: Additional patents may exist covering specific therapeutic uses of Maralixibat Chloride, such as its treatment of Alagille syndrome or other cholestatic liver diseases. These patents focus on the application of the known compound to treat specific conditions.
  • Example Patent Family: Patents related to the treatment of pruritus associated with specific liver diseases, including Alagille syndrome, are also relevant. For instance, patent applications and granted patents that specify dosages, patient populations, and treatment regimens are important.
• Process Patents: While composition of matter patents provide broad protection, patents covering specific, novel, and non-obvious synthetic routes or manufacturing processes for Maralixibat Chloride can also exist. These are crucial for API manufacturers seeking to produce the compound.
  • Considerations: API manufacturers must carefully assess the patent landscape to ensure their manufacturing processes do not infringe on any active process patents. This may involve developing alternative synthetic routes or obtaining licenses.
• Exclusivity Periods: Beyond patent protection, regulatory exclusivities (e.g., New Chemical Entity (NCE) exclusivity in the US, data exclusivity in Europe) can also extend market protection for the drug, influencing the timing of generic competition and the demand for third-party API supply.

How is Maralixibat Chloride formulated into a finished drug product?

Maralixibat Chloride is formulated into an oral solution for administration. The formulation process is critical for ensuring the stability, bioavailability, and palatability of the drug.

• Dosage Form: Oral solution.
• Key Excipients: The formulation typically includes excipients to enhance solubility, stability, palatability, and preservation. Common excipients in oral solutions include:
  • Solvents/Co-solvents: Purified water is the primary solvent. Co-solvents might be used if Maralixibat Chloride's aqueous solubility is limited.
  • Buffering Agents: To maintain a stable pH, which is crucial for the stability and solubility of the API. Examples include citrate, acetate, or phosphate buffers.
  • Sweeteners: To mask the taste of the API and improve palatability. Sucralose, sorbitol, or other high-intensity sweeteners are common.
  • Flavoring Agents: To further enhance taste.
  • Preservatives: To prevent microbial growth in multi-dose formulations. Sodium benzoate, potassium sorbate, or parabens are typical choices.
  • Viscosity Modifiers: May be included to improve mouthfeel and ease of administration, especially for pediatric populations. Cellulose derivatives or natural gums are examples.
• Manufacturing Process:
  1. API Weighing and Dissolution: Precisely weighed Maralixibat Chloride API is dissolved in the primary solvent (purified water), often with gentle heating if necessary.
  2. Excipient Preparation: Other excipients (buffers, sweeteners, flavors, preservatives) are dissolved in appropriate solvents.
  3. Mixing: The API solution and excipient solutions are combined under controlled conditions. The order of addition and mixing speed are critical to ensure homogeneity and prevent degradation.
  4. pH Adjustment: The pH of the final solution is adjusted to the target specification using buffering agents.
  5. Filtration: The solution may be sterile filtered, especially if the process is not terminal sterilization.
  6. Filling and Packaging: The final oral solution is filled into appropriate containers (e.g., amber glass bottles with calibrated droppers or dosing syringes) under aseptic conditions or in a controlled cleanroom environment.
• Stability Studies: Extensive stability studies are conducted on the finished drug product under various temperature and humidity conditions (ICH guidelines) to determine shelf life and recommended storage conditions.

Key Takeaways

• Maralixibat Chloride API supply is concentrated among specialized CDMOs with expertise in complex small molecule synthesis and cGMP manufacturing.
• Strict adherence to cGMP, ICH guidelines, and the submission of DMFs are mandatory for API manufacturers.
• The multi-step synthesis of Maralixibat Chloride, involving chiral centers and sensitive functional groups, presents significant manufacturing challenges.
• Key sourcing considerations include supplier capacity, regulatory compliance, supply chain security, technical expertise, IP landscape, and cost.
• The patent landscape for Maralixibat Chloride includes composition of matter, method of use, and potentially process patents, requiring careful due diligence for API manufacturers.
• The finished drug product is an oral solution, requiring specific formulation expertise to ensure API stability, bioavailability, and palatability.

Frequently Asked Questions

1. Who are the major generic API manufacturers for Maralixibat Chloride? Currently, information on specific generic API manufacturers publicly supplying Maralixibat Chloride is limited, suggesting a market dominated by originator-linked or highly specialized, non-publicly disclosed CDMOs.

2. What is the typical lead time for Maralixibat Chloride API batch production? Given the complexity of the synthesis, typical lead times for a custom API batch can range from 6 to 12 months, including process development, validation, and manufacturing.

3. Are there any specific challenges in sourcing the key raw materials for Maralixibat Chloride synthesis? Yes, sourcing specialized chiral building blocks, heterocyclic precursors, and high-purity reagents can present challenges due to their niche nature and potentially limited supplier base.

4. What is the expected market demand for Maralixibat Chloride API in the next five years? Market demand is tied to the prevalence of Alagille syndrome and other approved or investigated indications for Maralixibat Chloride. Precise forecasting requires detailed epidemiological data and market access evaluations.

5. How can a pharmaceutical company ensure the long-term supply reliability of Maralixibat Chloride API? Long-term supply reliability is best ensured through robust supplier qualification processes, dual sourcing strategies where feasible, strong contractual agreements, and proactive supply chain risk management.

---

Cited Sources

[1] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) Regulations. Retrieved from https://www.fda.gov/drugs/pharmaceutical-quality-industry-regulations/current-good-manufacturing-practice-cgmp-regulations

[2] European Medicines Agency. (n.d.). Good Manufacturing Practice (GMP). Retrieved from https://www.ema.europa.eu/en/human-regulatory/research-and-development/scientific-advice-and-protocols/good-manufacturing-practice-and-good-distribution-practice

[3] U.S. Food and Drug Administration. (2023, February 16). Drug Master Files (DMFs). Retrieved from https://www.fda.gov/drugs/drug-master-files-dmfs/drug-master-files-dmfs

[4] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2000). ICH Harmonised Tripartite Guideline: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients. Q7. Retrieved from https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q7/Step4/Q7_Guideline.pdf

[5] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2017). ICH Harmonised Guideline: Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological/Biological Entities). Q11. Retrieved from https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q11/Step4/Q11_Guideline.pdf

[6] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2006). ICH Harmonised Tripartite Guideline: Impurities in New Drug Substances. Q3A(R2). Retrieved from https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q3A_R2/Step4/Q3A_R2__Step4.pdf

[7] U.S. Patent and Trademark Office. (n.d.). United States Patent 7,906,518. Retrieved from USPTO database for patent details. (Specific patent number and details would be verified through direct USPTO search).